Inducers of immunogenic cancer cell death

被引：251

作者：

Dudek, Aleksandra M. ^{[1
]}

Garg, Abhishek D. ^{[1
]}

Krysko, Dmitri V. ^{[2
,3
]}

De Ruysscher, Dirk ^{[4
]}

Agostinis, Patrizia ^{[1
]}

机构：

[1] Univ Leuven KU Leuven, Dept Cellular & Mol Med, Cell Death Res & Therapy Unit, Louvain, Belgium

[2] VIB, Mol Signalling & Cell Death Unit, Dept Mol Biomed Res, Ghent, Belgium

[3] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium

[4] Univ Hosp Leuven KU Leuven, Dept Oncol, Louvain, Belgium

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2013年 / 24卷 / 04期

关键词：

Immunogenic cell death; ICD inducers; Cancer; Tumour immunology; Anti-tumour immunity; NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; INDUCED DNA DAMAGE; CALRETICULIN EXPOSURE; PHOTODYNAMIC-THERAPY; DENDRITIC CELLS; ANTITUMOR-ACTIVITY; STAT3; ACTIVATION;

D O I：

10.1016/j.cytogfr.2013.01.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Recently, cytokine-based pro-tumourigenic signalling has been found to play a major role in the immune system's pro-tumourigenic activity. On the other hand, other recent findings have shown that immunogenic cancer cell death triggered by certain anticancer modalities might reset the dysfunctional immune system towards the activation of a long-lasting protective anti-tumour response. Therefore, using inducers of immunogenic cell death (ICD) that can prevent or impede tumour-promoting cytokine signalling is one of the best ways of instigating or restoring efficient anti-tumour immunity. In this review it is discussed, how the different ICD inducers interact with the immune system and influence cytokine-based pro-tumourigenic signalling. We believe that it is crucial to discover or develop new anticancer therapeutic modalities that can induce ICD and impede tumour-promoting cytokine signalling. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：319 / 333

页数：15

共 168 条

[1]

Adams J, 1999, CANCER RES, V59, P2615

[2]

The proteasome: A suitable antineoplastic target [J].

Adams, J .

NATURE REVIEWS CANCER, 2004, 4 (05) :349-360

[3]

Photodynamic Therapy of Cancer: An Update [J].

Agostinis, Patrizia ;

Berg, Kristian ;

Cengel, Keith A. ;

Foster, Thomas H. ;

Girotti, Albert W. ;

Gollnick, Sandra O. ;

Hahn, Stephen M. ;

Hamblin, Michael R. ;

Juzeniene, Asta ;

Kessel, David ;

Korbelik, Mladen ;

Moan, Johan ;

Mroz, Pawel ;

Nowis, Dominika ;

Piette, Jacques ;

Wilson, Brian C. ;

Golab, Jakub .

CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (04) :250-281

[4]

Alecu M, 1998, ANTICANCER RES, V18, P4651

[5]

Immunogenicity of anthracyclines: moving towards more personalized medicine [J].

Apetoh, Lionel ;

Mignot, Grgoire ;

Panaretakis, Theocharis ;

Kroemer, Guido ;

Zitvogel, Laurence .

TRENDS IN MOLECULAR MEDICINE, 2008, 14 (04) :141-151

[6]

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Criollo, Alfredo ;

Ortiz, Carla ;

Lidereau, Rosette ;

Mariette, Christophe ;

Chaput, Nathalie ;

Mira, Jean-Paul ;

Delaloge, Suzette ;

Andre, Fabrice ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

IMMUNOLOGICAL REVIEWS, 2007, 220 :47-59

[7]

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[8]

Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes [J].

Audia, S. ;

Nicolas, A. ;

Cathelin, D. ;

Larmonier, N. ;

Ferrand, C. ;

Foucher, P. ;

Fanton, A. ;

Bergoin, E. ;

Maynadie, M. ;

Arnould, L. ;

Bateman, A. ;

Lorcerie, B. ;

Solary, E. ;

Chauffert, B. ;

Bonnotte, B. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) :523-530

[9]

Prognostic value of nuclear factor κ B expression in patients with advanced cervical cancer undergoing radiation therapy followed by hysterectomy [J].

Baiocchi, Glauco ;

Begnami, Maria Dirlei ;

Fukazawa, Elza Mieko ;

Rosa Oliveira, Renato Almeida ;

Faloppa, Carlos Chaves ;

Kumagai, Lillian Yuri ;

Badiglian-Filho, Levon ;

Assis Pellizzon, Antonio Cassio ;

Conte Maia, Maria Aparecida ;

Jacinto, Alexandre Arthur ;

Soares, Fernando Augusto ;

Lopes, Ademar .

JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (07) :614-618

[10]

RETRACTED: Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer (Retracted article. See vol. 78, pg. 5468, 2018) [J].

Banerjee, Sanjeev ;

Kaseb, Ahmed O. ;

Wang, Zhiwei ;

Kong, Deujan ;

Mohammad, Mussop ;

Padhye, Subhash ;

Sarkar, Fazlul H. ;

Mohammad, Ramzi M. .

CANCER RESEARCH, 2009, 69 (13) :5575-5583

← 1 2 3 4 5 6 7 8 9 10 →